PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 145-146
DOI: 10.4103/0971-5851.123699
GUEST EDITORIAL

Chronic myeloid leukemia in the Imatinib era - Compilation of Indian data from 22 centers involving 8115 patients

Purvish Parikh
Medical Oncologist and Hematologist, SAARC Federation of Oncology, Mumbai, Maharashtra, India
,
Shweta Bansal
Hemato-Oncologist, Ayurvihar Asian Institute of Oncology, K. J. Somaiya Campus, Sion, Mumbai, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
 als PDF herunterladen Lizenzen und Reprints
Preview Container


Publikationsverlauf

Artikel online veröffentlicht:
19. Juli 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Parikh PM, Charak BS, Banavali SD, Koppilar S, Giri NK, Kumar A, et al. Retrospective analysis of 224 cases of CML. Indian J Hematol 1988;6:85-7.
  • 2 Parikh PM, Iyer RS, Saikia TK, Gopal R, Advani SH. Philadelphia chromosome. J Assoc Physicians India 1992;40:98-100.
  • 3 Barbhaya SA, Parikh PM, Desai S. Bcr-c.abl detection by southern blotting in CML. Indian J Hematol 1993;11:27.
  • 4 Banavali SD, Parikh PM, Nanjangud G. Results of treatment of CML with a cisplatin based intensive treatment regimen (TMH 8802 protocol). Indian J Hematol 1993;11:244-51.
  • 5 Giles FJ, Hehlmann R, Hockhaus A, Parikh PM. Initial characterization of philadephia chromosome chronic phase CML: A comparison between Asian and German patients on the International Oncology Study Group the German CML study group protocol. Int J Hematol 1996;64:294.
  • 6 Saikia TK, Advani SH, Parikh PM, Bapna A, Somjee S, Mukhopadhyay A, et al. Results of Allogeneic Bone Marrow transplant in Chronic Myeloid Leukemia (CML) following conditioning with Busulfan and cyclophosphamide. J Assoc Physicians India 1999;47:770-3.
  • 7 Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
  • 8 O′Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008;112:76.
  • 9 Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation on behalf of the Omacetaxine 202 Study Group. Blood 2012;120:2573-80.